Financial Performance - Total revenue for Q3 2025 reached $126 million, an 18% increase compared to $107 million in Q3 2024[42] - Subscription revenue for Q3 2025 was $113 million, a 21% increase from $93 million in Q3 2024[42] - ARR (Annual Recurring Revenue) as of September 2025 reached $440 million, a 19% increase compared to $371 million in September 2024[42] - Adjusted EBITDA for Q3 2025 was $38 million, representing 30% of revenue, compared to $31 million and 29% in Q3 2024[42] - The company anticipates ARR to be between $460 million and $475 million for fiscal year 2025, representing a growth of 16% to 20%[72] - The company expects revenue to be between $470 million and $475 million for fiscal year 2025, representing a growth of 17% to 18%[72] - The company projects adjusted EBITDA to be between $124 million and $127 million for fiscal year 2025, with an adjusted EBITDA margin of 26% to 27%[72] Acquisition - Cellebrite is set to acquire Corellium for $170 million in cash, with an additional $30 million earn-out potential over 2 years, the deal is expected to close in Q4 2025[34] Market Position - Cellebrite has a global customer base of approximately 7,000 customers[8] - Cellebrite's solutions are used in over 1.5 million legally-sanctioned investigations in 2024[8] - Cellebrite serves over 3,000 state and local accounts in North America, including 72 out of the top 100[24]

Allogene Corporate Overview November 2025 Legal Disclaimers This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. To the extent that statements contained in this presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statem ...

KORU Medical Systems Q3 2025 Earnings Call November 12, 2025 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performa ...

Financial Performance - Revenue in 3Q25 reached $1273 million, with a 121% organic growth at constant currency year-over-year[23] - Adjusted EBITDA margin was 185% in 3Q25[23] - Adjusted profit margin was 89% in 3Q25[23] - Cash generated from operating activities in 9M25 was $465 million, with an operating cash flow/adjusted EBITDA of 718%[72] - Adjusted diluted EPS in 3Q25 was $009, a 16% year-over-year increase[77] Growth and Expansion - CI&Ters grew by 163% year-over-year, reaching 7,858 employees[31, 33] - The company is expanding its people platform for growth[30] - The company has a diversified revenue base, with financial services contributing 36%, consumer goods 20%, retail and industrial goods 21%, tech and telecom 10%, life sciences 8%, and others 5% of the total revenue in 9M25[61] - Latin America accounts for 47%, North America 44%, and new markets 10% of the total revenue by geography in 9M25[61] AI and Technology - CI&T is driving AI adoption internally, with rapid growth in its library of agents and adoption by CI&Ters[35, 36] - 85% adoption across CI&Ters with 64% daily active CI&Ters[38, 39]

Financial Performance - Q1 FY2026 revenue reached $14883 million, up 8% year-over-year[9, 26, 32, 33] - Non-GAAP EPS was $1.00, a 10% increase year-over-year[9] - Non-GAAP gross margin was 68.1%[9] - Non-GAAP operating margin was 34.4%[9] AI Momentum - Cisco secured $1300 million in AI infrastructure orders from hyperscale customers in Q1 FY26[6, 9, 18] - AI orders of over $200 million were taken from neocloud, sovereign, and enterprise customers in Q1 FY26[6, 18] - The company anticipates over $3000 million in AI infrastructure revenues in FY26[6, 12] - The AI opportunities pipeline is growing, exceeding $2000 million across neocloud, sovereign, and enterprise customers[9, 15] Recurring Revenue - Total RPO increased by 7% year-over-year to $42900 million, with product RPO up 10% year-over-year[9, 27] - Total ARR grew by 5% year-over-year to $31400 million, with product ARR up 7% year-over-year[9, 27] Capital Allocation - Cisco returned $3600 million to shareholders in Q1 FY26, including $2001 million in share repurchases[9, 35]

Financial Performance & Growth - 2024 Revenue was $3.4 billion[14] - 2024 Adjusted EBITDA was $761 million[15] - 2024 Adjusted EPS was $1.39[22] - Q3 2025 Revenue reached $856 million, a 3% year-over-year increase[27] - Q3 2025 Adjusted EBITDA margin improved by 90 basis points year-over-year to 22.9%[28] - Q3 2025 Adjusted EPS increased by 18% year-over-year to $0.39[28] Market Opportunities & Strategy - The company anticipates double-digit core growth in growth markets[38] - The company expects Personal Mobility revenue to more than double by 2028, with a Compound Annual Growth Rate (CAGR) of approximately 30%[41, 58] - The company sees a potential revenue opportunity of approximately $100 million to $200 million by 2028 from liquid-cooled Data Center applications[58] Financial Targets & Outlook - The company is on track to deliver its mid-term Adjusted EBITDA margin target in 2027[50] - The company anticipates end markets to recover in 2026, driving incremental earnings growth[58]

This presentation is made by Ibotta, Inc. (the "Company," "Ibotta," "our," or "we") and contains forward-looking statements that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: future operating results, guidance for Q4 2025 (including revenue and Adjusted EBITDA), our ability to grow our revenue and factors contributing to such potential revenue growth, our ability to real ...

Financial Performance Highlights - Alliance Entertainment's EBITDA soared to $122 million in Q1 FY26, a 259% year-over-year increase from $34 million[11] - Net income increased significantly from $04 million to $49 million[41, 137] - Adjusted EBITDA increased from $34 million to $122 million, a 258% increase year-over-year[43, 134] - Gross Margin increased by 340 basis points to 146%[133] Revenue and Sales - Alliance Entertainment drives over $1 billion in annual revenue across diverse categories[22] - Revenue for the twelve months ended September 30, 2025, was $1088 million[25] - Q1 FY26 revenue increased to $254 million from $229 million in Q1 FY25[32] - Direct-to-consumer (DTC) contributes 37% of Alliance Entertainment's net revenue[58] Balance Sheet - Inventory rose from $1028 million to $1217 million, reflecting holiday build[30, 135] - The Revolving Credit Facility, Net balance improved from $88 million to $56 million year-over-year[135] Strategic Initiatives and Partnerships - Alliance Entertainment has signed an exclusive multi-year Home Video and Digital Rights License Agreement with The Horror Section Inc[11] - Alliance Entertainment is the Category Advisor for Walmart's video category[63] - Exclusive distribution and licensing agreements drive annual sales exceeding $365 million[68]

INNOVATE Corp. Q3 2025 Earnings Release Supplement November 12, 2025 INNOVATE Corp. 2025 Safe Harbor Disclaimers Cautionary Statement Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains, and certain oral statements made by our representatives from time to time may contain, "forward-looking statements." Generally, forward-looking statements include information describing actions, events, results, strategies and expe ...

November 12, 2025 Third Quarter Financial and Business Update 1 DISCLAIMERS Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future c ...